Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

Oversubscribed financing co-led by HealthCap and EQT Life Sciences (formerly LSP); joined by Pureos Bioventures

Developing novel drugs for systemic targeted radiation therapy (STRT)

Proceeds will be used to advance lead radiopharmaceutical product, satoreotide, for the treatment of neuroendocrine cancers and certain other aggressive, hard-to-treat cancers

Led by industry veteran Manfred Rüdiger as CEO, and world-renowned expert in oncology and nuclear medicine, Sandy McEwan as CMO

BERLIN, 8 June 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, today announces the successful completion of an oversubscribed EUR 25 million Series A financing round. Ariceum was co-founded by EQT Life Sciences (formerly LSP) and HealthCap who also co-led the financing that was joined by Pureos Bioventures. Ipsen transferred assets, and all corresponding rights into the Company in late 2021.

Read more…

 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH